Abstract
The USA has traditionally been seen as the most attractive location for generic products, with the European generics market's development having been stifled by market fragmentation, low brand prices and a general distrust of copy products in some regions. This paper compares the changing dynamics of both European and US markets, and identifies which region is expected to offer generics players the best prospects for future growth. The impact of EU expansion and of recently introduced legislation in both Europe and the USA is assessed, and best practice portfolio management recommendations are evaluated with reference to the geographical region(s) in which companies operate.
Get full access to this article
View all access options for this article.
References
1.
Figures sourced from www.gphaonline.org.
2.
Generics, Supergenerics and Patent Strategies conference, 29th–30th March, Grange City Hotel, London.